Jeffrey M. Zirger,

Acting Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2018–13793 Filed 6–26–18; 8:45 am] **BILLING CODE 4163–18–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Availability of Program Application Instructions for Tribal MIPPA Program Funds

Title: Medicare Beneficiary Outreach and Assistance Program: Funding for Title VI Native American Programs.

Announcement Type: Initial. Funding Opportunity Number: HHS– 2018–ACL–MITRB–1802.

Statutory Authority: The statutory authority for grants under this program announcement is contained in Subsection (a)(1)(B) of section 119 of the Medicare Improvements for Patients and Providers Act of 2008, as amended by section 3306 of the Patient Protection and Affordable Care Act, section 610 of the American Taxpayer Relief Act of 2012, section 1110 of the Pathway for SGR Reform Act of 2013, and section 110 of the Protecting Access to Medicare Act of 2014, and section 208 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).

Catalog of Federal Domestic
Assistance (CFDA) Number: 93.071.
Dates: The deadline date for the

submission of applications is 11:59PM EST August 17, 2018.

I. Funding Opportunity Description

Section 110 of the Protecting Access to Medicare Act of 2014 extended funding for outreach and assistance for low income programs under the Medicare Improvements for Patients and Providers Act (MIPPA). Older Americans Act (OAA) Title VI Native American Programs can fill an important role in providing valuable support to help eligible Native American elders in accessing the Low Income Subsidy program (LIS), Medicare Savings Program (MSP), Medicare Part D, Medicare prevention benefits and screenings and in assisting beneficiaries in applying for benefits. The purpose of these MIPPA grants will be to help inform eligible Native American elders about these benefits. The Administration for Community Living (ACL) seeks certification from OAA Title VI Native American programs that they will use the funds to

coordinate at least one community announcement and at least one community outreach event to inform and assist eligible American Indian, Alaska Native or Native Hawaiian elders about the benefits available to them through Medicare Part D, the Low Income Subsidy, the Medicare Savings Program or Medicare prevention benefits and screenings and counsel those who are eligible.

II. Award Information

ACL/AoA has a total budget of \$270,000 for the Tribes and will provide a grant of at least \$1,000 to each Older Americans Act Title VI Native American grantee. ACL reserves the right to adjust funding levels subject to the number of applications received and availability of funds. ACL/AoA will award grants of at least \$1,000 to each Title VI Native American grantee for a period of 12 months. The example of at least \$1,000 per event is for illustrative purposes only. All expenditures must be properly documented and allowable per the terms and conditions of the grant award. The anticipated award date is on or before September 30, 2018.

III. Eligibility Criteria and Other Requirements

Only current Older Americans Act Title VI Native American Program grantees are eligible to apply for this funding opportunity. Cost Sharing or Matching is not required.

IV. Submission Information

The program instructions and onepage application template for this funding opportunity are available at www.grants.gov. At the website, search for HHS-2018-ACL-MITRB-1802.

To receive consideration, signed applications must be submitted by 11:59 p.m. Eastern time on August 17, 2018. No applications will be accepted after this date. Submit your signed application via:

(1) Email to MIPPA.Grants@ acl.hhs.gov. Include the State, Name of Tribe, and Title VI Part A Grant Number and the words "MIPPA Application" in the subject line; or

(2) Overnight mail (FedEx, UPS, or USPS) to: Administration for Community Living, Office of Grants Management, 330 C Street SW, Suite 1136B, Washington, DC 20201; Attention: Yi-Hsin Yan.

V. Agency Contacts

Direct inquiries regarding this funding opportunity to U.S. Department of Health and Human Services, Administration for Community Living, Administration on Aging, Washington, DC 20201, attention: Cecelia Aldridge or by calling (202) 795–7293 or by email Cecelia.Aldridge@acl.hhs.gov.

Dated: June 20, 2018.

Mary Lazare,

Principal Deputy Administrator.
[FR Doc. 2018–13811 Filed 6–26–18; 8:45 am]
BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration [Docket No. FDA-2018-N-2381]

The Food and Drug Administration's Comprehensive, Multi-Year Nutrition Innovation Strategy; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

SUMMARY: The Food and Drug Administration (FDA or we) is announcing the following public meeting entitled "FDA's Comprehensive, Multi-Year Nutrition Innovation Strategy." The purpose of the public meeting is to give interested persons an opportunity to discuss FDA's nutrition innovation strategy, including: A standard icon or symbol for the claim "healthy"; a more efficient review strategy for evaluating qualified health claims; statements or claims that could facilitate innovation to promote healthful eating patterns; approaches for modernizing standards of identity; possible changes that could make ingredient information more consumer friendly; and FDA's educational campaign for consumers about the updated Nutrition Facts Label that consumers will be seeing in the marketplace.

DATES: The public meeting will be held on July 26, 2018, from 8:30 a.m. until 5:30 p.m. Eastern Time. Submit either electronic or written comments on this public meeting by August 27, 2018. See the **SUPPLEMENTARY INFORMATION** section for registration date and information. ADDRESSES: The public meeting will be held at the Hilton Washington DC/ Rockville Hotel, 1750 Rockville Pike, Rockville, MD 20852. For more information on the hotel see http:// www3.hilton.com/en/hotels/maryland/ hilton-washington-dc-rockville-hoteland-executive-meeting-ctr-IADMRHF/ index.html.

You may submit comments as follows. Please note that late, untimely filed comments will not be considered.

Electronic comments must be submitted on or before August 27, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of August 27, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA–2018–N–2381 for "FDA's Comprehensive, Multi-Year Nutrition Innovation Strategy." Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as "Confidential

Submissions," publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." We will review this copy, including the claimed confidential information, in our consideration of comments. The second copy, which will have the claimed confidential information redacted/ blacked out, will be available for public viewing and posted on https:// www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

For questions about registering for the meeting or to register by phone: Melissa Schroeder, SIDEM, 1775 Eye St, NW, Suite 1150, Washington, DC 20006, 240–393–4496, EventSupport@ Sidemgroup.com.

For general questions about the meeting or for special accommodations due to a disability: Juanita Yates, Center for Food Safety and Applied Nutrition (HFS–009), Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–1731, email: Juanita.yates@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

FDA plays a critical role in promoting public health by, among other things, ensuring that food labeling provides consumers with reliable, evidence-based information so that they can make informed choices about the foods they purchase in order to maintain and improve their health through diet and nutrition. On January 11, 2018, FDA released its 2018 Strategic Policy Roadmap (https://www.fda.gov/ AboutFDA/ReportsManualsForms/ Reports/ucm591993.htm), which focuses, in part, on efforts to empower consumers to make better and more informed decisions about their diets and health, foster the development of healthier food options, and expand the opportunities to use nutrition to reduce morbidity and mortality due to chronic disease. The roadmap highlights FDA's commitment to finding approaches to advance policies that better achieve these goals.

On March 29, 2018, FDA Commissioner Dr. Scott Gottlieb, M.D. announced a comprehensive, multi-year FDA Nutrition Innovation Strategy (hereinafter the "FDA Nutrition Innovation Strategy") (to access the speech, visit https://www.fda.gov/ NewsEvents/Speeches/ucm603057.htm). The Nutrition Innovation Strategy seeks to promote public health through improved nutrition, encourage industry innovation to create healthy products that consumers seek, and address ways for consumers to identify those products. In implementing the Nutrition Innovation Strategy, FDA is committed to providing opportunities for public input to help with these initiatives. Early and active engagement from stakeholders and the public will help to inform FDA's thinking and policy actions.

II. Topics for Discussion at the Public Meeting

FDA will host a 1-day meeting to provide stakeholders and other interested persons an opportunity to have an in-depth discussion on various aspects of the FDA Nutrition Innovation Strategy and to provide input on ways to modernize FDA's approach to better protect public health while removing barriers to industry innovation. FDA expects that the topics addressed at the meeting will include the following (a more detailed agenda will be made available prior to the meeting):

• Considering using a standard icon to denote the claim "healthy" on food labels.

- Creating a more efficient review strategy for evaluating qualified health claims on food labels.
- Discussing new or enhanced labeling statements or claims that could facilitate innovation to produce more healthful foods and more healthful consumer food choices.
- Modernizing the standards of identity to provide more flexibility for the development of healthier products, while making sure consumers have accurate information about these food products.
- Providing opportunities to make ingredient information more helpful to consumers.
- FDA's educational campaign for consumers about the updated Nutrition Facts Label.

We invite interested parties to provide information on the above and other topics related to the FDA Nutrition Innovation Strategy.

III. Participating in the Public Meeting

Registration: To register for the public meeting, please visit the following website: https://www.fda.gov/Food/
NewsEvents/WorkshopsMeetings
Conferences/default.htm. Please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone.

Registration is free and based on space availability, with priority given to early registrants. Persons interested in attending this public meeting must register by July 19, 2018, midnight Eastern Time. Early registration is recommended because seating is limited; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been accepted.

If you need special accommodations due to a disability, please contact Juanita Yates (see FOR FURTHER INFORMATION CONTACT) no later than July 12, 2018.

Requests for Oral Presentations: During online registration you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments and requests to participate in the focused sessions. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. All requests to make oral presentations must be

received by July 12, 2018, midnight Eastern Time. We will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by July 16, 2018. Speakers will be limited to making oral remarks; there will not be an opportunity to display materials such as slide shows, videos, or other media during the meeting. No commercial or promotional material will be permitted to be presented or distributed at the public meeting.

Streaming Webcast of the Public Meeting: This public meeting will also be webcast. Webcast participants are asked to preregister at https:// www.fda.gov/Food/NewsEvents/ WorkshopsMeetingsConferences/ default.htm.

Transcripts: Please be advised that as soon as a transcript of the public meeting is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff (see ADDRESSES). A link to the transcript will also be available on the internet at https://www.fda.gov/Food/NewsEvents/WorkshopsMeetings Conferences/default.htm.

Other Issues for Consideration: A summary of key information on participating in the meeting follows:

TABLE 1—INFORMATION ON PARTICIPATION IN THE MEETING

Date	Address	Preregister	Electronic address	Request to make an oral presentation	Special accommodations	Submit either electronic or written comments
July 26, 2018 from 8:30 a.m. until 5:30 p.m. EDT.	Hilton Washington DC/Rockville Hotel, 1750 Rockville Pike, Rockville, MD 20852.	July 19, 2018: Closing date for registration.	https://www.fda.gov/ Food/ NewsEvents/ WorkshopsMeeti- ngsConferences/ default.htm.	July 12, 2018	July 12, 2018: closing date to request special accommodations due to a disability.	Submit Comments to: https://www.regulations.gov, or Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Dated: June 22, 2018.

Leslie Kux,

 $Associate\ Commissioner\ for\ Policy.$ [FR Doc. 2018–13831 Filed 6–26–18; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Tick-Borne Disease Working Group

AGENCY: Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) announces the

seventh meeting of the Tick-Borne Disease Working Group (Working Group) on July 24, 2018, from 10:00 a.m. to 4:00 p.m., Eastern Time. The seventh meeting will be an on-line meeting held via webcast. The Working Group will review and vote on the content of the five chapters that will be included in the Working Group's Report to Congress.

DATES: The on-line meeting will be held on July 24, 2018, from 10:00 a.m. to 4:00 p.m. Eastern Time.

ADDRESSES: This will be an on-line meeting that is held via webcast. Members of the public may attend the meeting via webcast. Instructions for attending this virtual meeting will be posted prior to the meeting at: https://

www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/index.html.

FOR FURTHER INFORMATION CONTACT:

James Berger, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services; via email at *tickbornedisease@hhs.gov* or by phone at 202–795–7697.

SUPPLEMENTARY INFORMATION: The Working Group invites public comment on issues related to the Working Group's charge. Comments may be provided over the phone during the meeting or in writing. Persons who wish to provide comments by phone should review directions at https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/index.html before submitting a request via email at tickbornedisease@hhs.gov on or before July 19, 2018.